- 大会
- 英卡思亚洲年会 - 2025年 6月
- 英卡思中国大会 - 2025年 7月
- 英卡思巴黎国际年会 - 2026年 1月
- 英卡思美洲年会 - 2026年 3月
- 大师精品课
- 英卡思印度大会 - 2025年 11月
- 大会
- 英卡思亚洲年会 - 2025年 6月
- 英卡思中国大会 - 2025年 7月
- 英卡思巴黎国际年会 - 2026年 1月
- 英卡思美洲年会 - 三月 2026
- 大师精品课
- 英卡思印度大会 - 2025年 11月

英卡思学院

注册新账号

介绍
注册
大会日程
讲者
至尊晚宴
英卡思个人参会日程
赞助企业名单
认证

回到上页

2025 英卡思亚洲年会
大会日程

针对您所在时区的直播课程/会议的时间

时区参照: (UTC+07:00) Asia, Bangkok

时区

时区:改换时区

If you are logged in, change your default time zone in your account

GLP-1 and weight loss

会议室： Room 4 - Level 2
日期： 2025年 6月 8日星期日从 15:00 至 16:00
组织形式： 聚焦课程 > 涵盖大会的一个主要议题

主席

Roger CHEN 医师

内分泌科医师

澳大利亚

Simone MAY 医师

医师

奥地利

本场演讲内容

小时	讲者	演讲标题	讲稿摘要	数字
15:00	Roger CHEN 医师	Meet the expert: From GLP-1 to GIP/GLP-1 - Unveiling GIP's emerging role in obesity and beyond	查看	148813
15:15	Hugues CARTIER 医师	GLP-1: Yes or no to injectables for facial hollowing?		148812
15:30	Chiranjiv CHHABRA 医师	Integrating GLP-1 receptor agonists with noninvasive body countoring modalities for a holistic, more effective, and faster outcome	查看	148815
15:45		Discussion and Q&A		147036

进入前一场会议

进入下一场会议

推荐会议

解剖注射原理

美容规范

联合疗法

光声电仪

微生物组

Roger CHEN 医师

内分泌科医师

澳大利亚

其他作者 :

Meet the expert: From GLP-1 to GIP/GLP-1 - Unveiling GIP's emerging role in obesity and beyond

Objectives: This session will review the evolving scientific understanding of incretin-based therapies, with a focus on GIP (Glucose-dependent Insulinotropic Polypeptide).

Emerging clinical data on the role of GIP in advancing the treatment landscape of obesity and other weight-related co-morbidities will be reviewed.

Introduction: Advances in incretin-based therapies have led to the development of dual Glucose-dependent Insulinotropic Polypeptide (GIP)/Glucagon-like peptide-1 (GLP-1) receptor agonists, representing a new frontier in obesity management. While GLP-1 receptor agonists have shown clinical success, the addition of GIP to a GLP-1 receptor agonistsmay offer synergistic benefits through distinct and complementary mechanisms that may enhance treatment outcomes.

Materials / method: The emerging role of GIP in obesity and obesity-related comorbidities will be reviewed.

Results: GIP acts on multiple tissues, notably adipose tissue where it contributes directly to improved lipid buffering capacity and body composition. In the central nervous system, GIP may synergistically reduce food intake while attenuating GLP-1-induced nausea, potentially improving overall tolerability. Therapies which target dual incretin receptors appear to potentially overcome efficacy limitations which may be seen with selective with GLP-1 monotherapy.

Conclusion: Efficacy data using Glucose-dependent Insulinotropic Polypeptide (GIP)/Glucagon-like peptide-1 (GLP-1) receptor agonists have led to a resurgence of research on the fascinating and emerging role of GIP in obesity

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否
请注明名称（个人，公司，学会等等）: As

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： I am a speaker for or on advisory boards for Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Zuellig Pharma

Hugues CARTIER 医师

皮肤科医师

法国

其他作者 :

GLP-1: Yes or no to injectables for facial hollowing?

Chiranjiv CHHABRA 医师

皮肤科医师

印度

其他作者 :

Integrating GLP-1 receptor agonists with noninvasive body countoring modalities for a holistic, more effective, and faster outcome

Objectives: GLP 1 receptor agonists are as a boon for individuals suffering from obesity or overweight .A large section of people with obesitty ,who want fat loss through non invasive body countouring modalities yaketaking very long to reacht their target weight and shape because of difficulty in persisting with changed diet plans . The GLP 1 drugs reduce appetite , food cravings and result in upto 25 % weight loss.Rapid loss results in skin laxity and muscle loss . Thus adding technologies for skin tightening , muscle stregthening and localized fat loss are beneficial in achieving a holistic outcome

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of obesity by promoting significant weight loss.Results of Non invasive fat loss modalities like Cryolipolysis,Green light laser,RF or Cavitation can be improved by adding these medications.Also rapid weight reduction induced by these medications often leads to aesthetic challenges like volume loss, skin laxity, and body contour irregularities. These consequences of GLP-1-induced weight loss can be minimised by modalities for tightening and muscle toning modalities like MNRF,RF and HIFEM.

Materials / method: As a scientific fat loss clinic we are integrating GLP-1 Rec agonist with other modalities.Identify patients with BMI above 29 .Their Hb1AC can be in range or raised. Few investigations are done and they are suggested a comprehensive plan with GLP -1&GIP rec Agonist along with the required modality.Their doses is monitored by a team of physicians and endocrinologist.During the treatment we identify key aesthetic concerns associated with GLP-1-induced weight loss and and depending on that add modalities like dermal fillers, biostimulatory agents and energy-based devices.

Results: A combination of GLP-1 Rec agonist along with other modalities delivers faster and more gratifying results instead of any standalone treatment.

Conclusion: As GLP-1 agonists become a key in treating obesity, their aesthetic implications have initiated a proactive response from aestheticians. To address facial volume loss, skin laxity, and body contour challenges we need combination of injectable treatments, energy-based devices, and, in some cases, surgical interventions. Future research should focus on understanding the molecular mechanisms of skin and fat changes and developing protocols &guidelines for treating this unique patient population

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Discussion and Q&A

大会

N O W

在泰国曼谷

您有问题要问？

在我们的常见问题解答中快速找到答案

大会

英卡思亚洲年会
英卡思中国大会
英卡思巴黎国际年会
英卡思美洲年会

关于我们

公司
隐私政策
法律信息

学院

主页
课程
Webinars
探索
博客

支援

教育援助

保持联系

联系我们

登录名/电邮地址

密码

保持登录状态

密码遗失 ? 还没有账号？现在注册

保持登录状态

academy.Do_not_have_an_account_yet 现在注册

2025 英卡思亚洲年会 大会日程

GLP-1 and weight loss

主席

本场演讲内容

推荐会议

2025 英卡思亚洲年会
大会日程

本场演讲内容